Rational biomarker development for the early and minimally invasive monitoring of AML.
Sherif AbdelhamedJohn T ButlerSeul K JungDing-Wen ChenGaye JenkinsLina GaoJeong Y LimJeffery M KlcoTerzah M HortonPeter KurrePublished in: Blood advances (2021)
Recurrent disease remains the principal cause for treatment failure in acute myeloid leukemia (AML) across age groups. Reliable biomarkers of AML relapse risk and disease burden have been problematic, as symptoms appear late and current monitoring relies on invasive and cost-ineffective serial bone marrow (BM) surveillance. In this report, we discover a set of unique microRNA (miRNA) that circulates in AML-derived vesicles in the peripheral blood ahead of the general dissemination of leukemic blasts and symptomatic BM failure. Next-generation sequencing of extracellular vesicle-contained small RNA in 12 AML patients and 12 controls allowed us to identify a panel of differentially incorporated miRNA. Proof-of-concept studies using a murine model and patient-derived xenografts demonstrate the feasibility of developing miR-1246, as a potential minimally invasive AML biomarker.
Keyphrases
- acute myeloid leukemia
- minimally invasive
- allogeneic hematopoietic stem cell transplantation
- bone marrow
- peripheral blood
- cell proliferation
- end stage renal disease
- public health
- mesenchymal stem cells
- ejection fraction
- long non coding rna
- newly diagnosed
- prognostic factors
- physical activity
- acute lymphoblastic leukemia
- gene expression
- sleep quality
- depressive symptoms
- replacement therapy
- human health
- circulating tumor cells